LBA36Association of PD-L1 expression and gene expression profiling with clinical response to pembrolizumab in patients with advanced recurrent ovarian cancer: Results from the phase II KEYNOTE-100 study. (23rd October 2018) - Ledermann, J A; Shapira-Frommer, R; Santin, A; Lisyanskaya, A S; Pignata, S; Vergote, I; Raspagliesi, F; Sonke, G S; Birrer, M J; Provencher, D M; Sehouli, J; Colombo, N; et al.